68P - Paclitaxel plus bevacizumab in patients with chemoresistant relapsed small cell lung cancer as salvage treatment: a phase II multicenter study of th...

Date 28 March 2014
Event ELCC 2014
Session Lunch and poster display session
Topics Anti-Cancer Agents & Biologic Therapy
Small-Cell Lung Cancer
Presenter Giannis Mountzios
Citation Journal of Thoracic Oncology (2014) 9 (Supplement 9): S7-S52. 10.1097/JTO.0000000000000131
Authors G. Mountzios1, C. Emmanouilidis2, N. Vardakis2, E. Kontopodis2, D. Hatzidaki2, E. Popis2, N. Karachaliou2, A. Kotsakis2, M. Agelidou2, V. Georgoulias2
  • 1Medical Oncology, 251 Airforce General Hopsital, 11525 - Athens/GR
  • 2Medical Oncology, University of Crete School of Medicine, Herakleion/GR


Therapeutic options for patients with relapsed, chemo-resistant small-cell lung cancer (SCLC) are limited. Since paclitaxel has demonstrated single-agent activity in the second-line setting of SCLC and angiogenesis seems to play an important role in the pathogenesis of the disease, a phase II trial was conducted in order to evaluate the efficacy and the tolerance of their combination in patients with relapsed, chemo-resistant SCLC.